Switch theme
Sign up to access all valuation multiples
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.
2019
80
LTM Revenue n/a
LTM EBITDA n/a
$53.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pentixapharm Holding has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Pentixapharm Holding achieved revenue of $26K and an EBITDA of -$6.3M.
Pentixapharm Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pentixapharm Holding valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $33K | $26K | XXX | XXX | XXX |
| Gross Profit | $2.8M | $4.3M | XXX | XXX | XXX |
| Gross Margin | 8384% | 16546% | XXX | XXX | XXX |
| EBITDA | -$0.7M | -$6.3M | XXX | XXX | XXX |
| EBITDA Margin | -2145% | -24517% | XXX | XXX | XXX |
| Net Profit | -$2.7M | -$2.1M | XXX | XXX | XXX |
| Net Margin | -8039% | -8171% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pentixapharm Holding's stock price is EUR 3 (or $3).
Pentixapharm Holding has current market cap of EUR 62.1M (or $66.7M), and EV of EUR 49.7M (or $53.3M).
See Pentixapharm Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $53.3M | $66.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pentixapharm Holding has market cap of $66.7M and EV of $53.3M.
Pentixapharm Holding's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Pentixapharm Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pentixapharm Holding and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $53.3M | XXX | XXX | XXX |
| EV/Revenue | 2069.3x | XXX | XXX | XXX |
| EV/EBITDA | -8.4x | XXX | XXX | XXX |
| P/E | -8.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPentixapharm Holding's NTM/LTM revenue growth is n/a
Pentixapharm Holding's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Pentixapharm Holding's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pentixapharm Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pentixapharm Holding and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -24517% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 785% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1671% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5771% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 34608% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 45338% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pentixapharm Holding acquired XXX companies to date.
Last acquisition by Pentixapharm Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Pentixapharm Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pentixapharm Holding founded? | Pentixapharm Holding was founded in 2019. |
| Where is Pentixapharm Holding headquartered? | Pentixapharm Holding is headquartered in Germany. |
| How many employees does Pentixapharm Holding have? | As of today, Pentixapharm Holding has 80 employees. |
| Is Pentixapharm Holding publicy listed? | Yes, Pentixapharm Holding is a public company listed on FRA. |
| What is the stock symbol of Pentixapharm Holding? | Pentixapharm Holding trades under PTP ticker. |
| When did Pentixapharm Holding go public? | Pentixapharm Holding went public in 2024. |
| Who are competitors of Pentixapharm Holding? | Similar companies to Pentixapharm Holding include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Pentixapharm Holding? | Pentixapharm Holding's current market cap is $66.7M |
| What is the current revenue growth of Pentixapharm Holding? | Pentixapharm Holding revenue growth between 2023 and 2024 was -23%. |
| Is Pentixapharm Holding profitable? | Yes, Pentixapharm Holding is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
